New York State Common Retirement Fund
ACRV icon

New York State Common Retirement Fund’s Acrivon Therapeutics ACRV Stock Holding History

New York State Common Retirement Fund’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,314
Closed -$4.7K – 3200
2025
Q1 		$4.7K Hold
2,314
– – ﹤0.01% 3129
2024
Q4 		$13.9K Hold
2,314
– – ﹤0.01% 3090
2024
Q3 		$16.2K Hold
2,314
– – ﹤0.01% 3066
2024
Q2 		$13.4K Buy
2,314
+41
+2% +$330 ﹤0.01% 3231
2024
Q1 		$16.3K Hold
2,273
– – ﹤0.01% 3161
2023
Q4 		$11.2K Sell
2,273
-24
-1% -$127 ﹤0.01% 3188
2023
Q3 		$22K Buy
2,297
+22
+1% +$254 ﹤0.01% 3169
2023
Q2 		$29.5K Buy
2,275
+69
+3% +$835 ﹤0.01% 3212
2023
Q1 		$28K Buy
+2,206
New +$37K ﹤0.01% 3079

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

New York State Common Retirement Fund's ACRV Position: Q2 2025 in Review

New York State Common Retirement Fund sold out of Acrivon Therapeutics (ACRV) in Q2 2025, closing a stake of 2,314 shares — an estimated $4.7K sold.

New York State Common Retirement Fund first reported a position in ACRV in Q1 2023 and held it in 9 quarters. The position peaked at $29.5K in Q2 2023. 53 funds tracked by Wall St. Rank hold ACRV as of Q2 2025.

  • New York State Common Retirement Fund reported no remaining Acrivon Therapeutics position as of Q2 2025 after selling out during the quarter.
  • New York State Common Retirement Fund sold 2,314 Acrivon Therapeutics shares in Q2 2025, an estimated $4.7K.
  • New York State Common Retirement Fund first reported a position in Acrivon Therapeutics in Q1 2023 and held it in 9 quarters.
  • New York State Common Retirement Fund's Acrivon Therapeutics position peaked at $29.5K in Q2 2023.
  • 53 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2025.

Based on New York State Common Retirement Fund's 13F filing for Q2 2025, filed 13 Aug 2025.